Atea Pharmaceuticals

Atea Pharmaceuticals

AVIR· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +6.6% in FY2025

Jean-Pierre Sommadossi, PhD is the CEO of Atea Pharmaceuticals and was paid $3.4M in FY2025 (Dec), down 19%.

Pay$100 in the stock at the end of FY20 → $9
CEO pay is from each Atea Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Jean-Pierre Sommadossi, PhDFY2025
  2. 2Janet Hammond, MD, PhDFY2025
  3. 3Andrea CorcoranFY2025
  4. 4Maria Arantxa Horga, MDFY2025
  5. 5John VavrickaFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Atea Pharmaceuticals paid its 5 named executives $9.7M in total in FY2025 (Dec). CEO Jean-Pierre Sommadossi, PhD was paid $3.4M of that.

Name
Jean-Pierre Sommadossi, PhDPresident, Chief Executive Officer and Chairman of the Board
Janet Hammond, MD, PhDChief Development Officer
Andrea CorcoranChief Financial Officer, Executive Vice President, Legal
Maria Arantxa Horga, MDChief Medical Officer
John VavrickaChief Commercial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers19

See all

The FY2025 (Dec) proxy of Atea Pharmaceuticals names 19 peer companies for pay. Among Atea Pharmaceuticals and these peers, CEO pay was 4th highest of 6 and total shareholder return was the lowest of 6.

4th highest of 6in Atea Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:

$1.4M$33.3M

6th highest of 6in Atea Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:

$9$487

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board1

See all
  • Bruce Polsky, M.D.Director · 9 yr on the boardIndependentCompensation, Strategy and Public Policy—Paid as an executive

The board of the latest proxy (FY2023).

Activity

  1. Pay
    Atea Pharmaceuticals Division head pay fell 14% to $1.6M. The stock rose 7% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Atea Pharmaceuticals Division head pay fell 12% to $1.2M. The stock rose 7% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Atea Pharmaceuticals CEO pay fell 19% to $3.4M. The stock rose 7% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Atea Pharmaceuticals Division head pay fell 18% to $1.8M. The stock rose 7% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Atea Pharmaceuticals CFO pay fell 12% to $1.7M. The stock rose 7% in FY2025 (Dec).
    DEF 14A
  6. Pay
    Atea Pharmaceuticals Division head pay fell 77% to $1.8M. The stock fell 46% in FY2022 (Dec).
    DEF 14A
  7. Pay
    Atea Pharmaceuticals CEO pay fell 29% to $4.2M. The stock rose 10% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Atea Pharmaceuticals CEO pay fell 83% to $5.9M. The stock fell 46% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Atea Pharmaceuticals Division head pay fell 77% to $2.1M. The stock fell 46% in FY2022 (Dec).
    DEF 14A
  10. Pay
    Atea Pharmaceuticals CFO pay fell 77% to $2.0M. The stock fell 46% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 27, 2026FY2025
Annual report10-KMar 5, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KMar 6, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data